Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.
about
In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinoloneSingle-molecule sequencing reveals the molecular basis of multidrug-resistance in ST772 methicillin-resistant Staphylococcus aureus.Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureusBiological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections.Molecular detection of antimicrobial resistanceMutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with aPrevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory seInduction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin.Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistanceAntimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.Antibiotic resistances of starter and probiotic strains of lactic acid bacteria.Transmission and microevolution of USA300 MRSA in U.S. households: evidence from whole-genome sequencing.Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.Mechanisms of drug resistance: quinolone resistance.In vitro evaluation of the potential for resistance development to ceragenin CSA-13.In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.Identification of the enzyme responsible for N-acetylation of norfloxacin by Microbacterium sp. Strain 4N2-2.Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.Large tandem chromosome expansions facilitate niche adaptation during persistent infection with drug-resistant Staphylococcus aureusUse of a three-dimensional microarray system for detection of levofloxacin resistance and the mec A gene in Staphylococcus aureus.Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance.Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.Real-time PCR assay for detection of fluoroquinolone resistance associated with grlA mutations in Staphylococcus aureus.MRSA Isolates from United States Hospitals Carry dfrG and dfrK Resistance Genes and Succumb to Propargyl-Linked Antifolates.In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteriaPersistence of Mycoplasma hyopneumoniae in experimentally infected pigs after marbofloxacin treatment and detection of mutations in the parC gene.Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.In vitro activities of novel des-fluoro(6) quinolone BMS-284756 against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with different quinolones.Phenotypic and genotypic evaluation of fluoroquinolone resistance in clinical isolates of Staphylococcus aureus in Tehran.Prevalence and Genetic Basis of Antimicrobial Resistance in Non-aureus Staphylococci Isolated from Canadian Dairy Herds.
P2860
Q24629223-55B523A4-FED1-4764-B4CE-A529A57DB9E3Q30650682-E546CA0B-8EAE-4372-B3CE-C639F35CA5BCQ33836597-76BBC50E-216E-492D-AB49-9BCBA774C9F6Q33836664-8F4EDDBB-83B1-4471-ABDE-0830DC93EA8EQ33975793-C3F1B025-5E5E-4860-9200-2B556A67797EQ33976741-121811DF-3E7E-4E9F-8E25-DCE22F633419Q33977480-5E1B4711-D4C6-4533-84F8-CCA4810A7079Q33978849-177B6702-CCA1-4E8E-80BF-B474BB9E6982Q33979593-063E695C-2B68-46C7-AB42-5DB4A2434A77Q33980689-B9E7E658-05A0-4AF3-93FB-A3627C7C11EEQ33980747-D715A59D-40F2-4D8C-B528-4DC6F58C7186Q33983092-AD78C93C-8ED6-46A1-97EF-56924A7E6DFFQ34106284-1483746E-8057-4CE2-9272-1698FE160181Q34139244-0061E59F-FDB7-4E62-BFF1-87F78E823A94Q35642002-64FCBA21-3321-47E5-9152-EE9EF4A86D5CQ35677499-5E62E106-A5C3-4650-AB8A-F34505D83D61Q36048167-73890B65-8C63-4536-BB8D-3E164F540EDAQ36225422-CFF0509D-FDD7-40E5-A7CB-E2DB22CEC7A5Q36308072-F5D8AD11-3EEF-41DC-8CC8-C3B3AB5F1EF8Q36492244-99A9CCBC-CB07-42AF-95B0-C82E72052B6EQ36505966-AEE93756-7CBE-4E71-812C-EA57B7E8FB6AQ37624733-81504618-E29E-4E05-9BB4-D3256140D728Q37658042-4146A2A7-DB35-4774-B939-5633E531A831Q38320231-5A568243-AED8-46EE-A657-9F5F87483B67Q38906198-4243A475-7B3A-4853-9B41-BFCAC3F2EC93Q39471404-32470475-372A-493E-993F-B530CC7004F4Q39472007-539D8C66-5D92-4DB5-A914-CCB18279A468Q39476686-734AA0D6-1EAB-485E-AB8E-AAE8B5251F05Q39477241-43F25115-9B9F-47BA-9945-E37B024AAD67Q39559548-64E3CC37-679B-4BDE-934F-289A0ECCB71AQ39652121-07FA22DC-C133-4411-896D-228CF5FA0BDEQ39660010-FC59BFB5-54BB-4B38-A6F9-43B650248A9BQ39789567-BE320CC3-9D03-4741-9C19-479D93A9372FQ40414676-569423A8-22D0-44F7-BE00-F17446D6F5B8Q41668866-3EF351EE-5A3C-410D-B7B8-D1F2D7F78036Q42408712-589A4FAC-5352-4140-89FE-1843E7FC407FQ42408718-8092C8DC-1BCE-447D-A9AD-76761D4570ADQ42782033-C1CD8EF8-43CE-4615-B8C6-CC77CA0B8D5AQ43103973-6B01AB23-8BDB-4F1A-A077-40255283C4F7Q50351287-ADBD412F-FF6E-4F8B-8F46-2228CAA282AB
P2860
Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
name
Characterization of grlA, grlB ...... utations on ciprofloxacin MIC.
@ast
Characterization of grlA, grlB ...... utations on ciprofloxacin MIC.
@en
type
label
Characterization of grlA, grlB ...... utations on ciprofloxacin MIC.
@ast
Characterization of grlA, grlB ...... utations on ciprofloxacin MIC.
@en
prefLabel
Characterization of grlA, grlB ...... utations on ciprofloxacin MIC.
@ast
Characterization of grlA, grlB ...... utations on ciprofloxacin MIC.
@en
P2093
P2860
P1476
Characterization of grlA, grlB ...... utations on ciprofloxacin MIC.
@en
P2093
F J Schmitz
M Lückefahr
S Scheuring
P2860
P304
P407
P577
1998-05-01T00:00:00Z